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1 Abbreviations: APC, allophycocyanin; -BRET, bioluminescence resonance energy transfer; CFP, cyan fluorescent protein; ER, endoplasmic reticulum; GFP, green fluorescent protein; FRET, fluorescence resonance energy transfer; IL8, interleukin 8/CXCL8; TR-FRET, time-resolved fluorescence resonance energy transfer; YFP, yellow fluorescent protein.
In recent times the concept that G proteincoupled receptors ( 1 GPCRs) can exist as dimers and/or higher order oligomers has become increasingly accepted (1) (2) (3) (4) (5) . Techniques ranging from the coimmunoprecipitation of co-expressed but differentially epitope-tagged forms of a single receptor species (6) (7) to the use of resonance energy transfer-based methods (8) (9) (10) (11) (12) have provided support for the presence of such dimers/oligomers for many GPCRs in transfected cell systems and the application of atomic force microscopy has shown the presence of dimers and arrays of dimers of rhodopsin in murine rod outer segment discs (13) (14) . In many cases, GPCR quaternary structure seems to be defined early in the processes of receptor synthesis and maturation with the GPCR being transported to the cell surface as a preformed dimer/oligomer (15) (16) (17) , the structure of which is unaffected by the presence of agonist ligands. The potential quaternary structure of a range of chemokine receptors has also been explored using similar approaches (18) (19) (20) (21) (22) (23) . Although a substantial number of chemokine receptors have been shown to possess such quaternary structure, a number of features of certain chemokine receptors are either controversial or seem not to follow the general model outlined above. For example, dimerization/oligomerization of a number of chemokine receptors appears to be promoted by the binding of chemokine ligands (18) (19) . Equally, it appears that mutation of certain chemokine receptors to prevent dimerization does not restrict membrane delivery (24) . Amongst the chemokine receptors (25) the closely related CXCR1 and CXCR2 receptors share a common agonist ligand in interleukin 8 (IL8, also called CXCL8). They are widely co-expressed on immune cells, including neutrophils, CD8(+) T cells and mast cells and non-competitive allosteric inhibitors of these receptors have been suggested to offer a general means to inhibit polymorphonuclear cell recruitment in vivo (26) . Recently, Trettel et al., (23) have reported that the CXCR2 receptor forms a constitutive dimer when expressed in HEK293 cells and also in cerebellar neurons in which it is expressed endogenously. By contrast, these workers reported that the CXCR1 receptor was unable to dimerize (23) . As well as homodimeric/oligomeric interactions, many related GPCRs have been shown to have the capacity to form hetero-dimers. This can result in alterations in receptor pharmacology and signal transduction characteristics (27) (28) (29) . A number of chemokine receptors have been reported to have the capacity to form hetero-dimers (30) but again, Trettel and co-workers (23) reported lack of interactions between the CXCR1 and CXCR2 receptors following their co-expression. Given the general parsimony of structure and function of closely related proteins we decided to reexamine the capacity of the CXCR1 and CXCR2 receptors to form homo-and hetero-dimers. Using a wide range of approaches we show that both CXCR1 and CXCR2 form homo-dimer/oligomers at an early stage in synthesis and maturation and that when co-expressed CXCR1 and CXCR2 form hetero-dimers as effectively as homo-dimers. The extent of neither the CXCR1-CXCR2 hetero-dimer nor the corresponding homo-dimers is affected by the presence of IL8.
amplified fragment digested and ligated into pcDNA3. c-myc-CXCR1 Sense:5'AAAAGAATTCGCCACCATGG AACAAAAACTTATTTCTGAAGAA GATCTGTCAAATATTACAGATCCAC 3' Antisense:5'AAAAGAATTCTCAGAGGTTG GAAGAGACATTGAC 3'. EcoRI sites are underlined and the amplified fragment digested and ligated into pcDNA3.
HA-CXCR1
Sense:5'AAAAGGTACCGCCACCATGT ATCCCTACGACGTCCCCGATTAT GCGTCAAATATTACAGATCCAC 3' Anti-sense: 5' AAAAGAATTCTCAGAGGTTGGAAGA GACATTGAC 3'. A KpnI site present in the sense primer and an EcoRI site present in the anti-sense primer are underlined and the amplified fragment digested and ligated into pcDNA3. To generate the endoplasmic reticulum (ER) trapped form of HA-CXCR1 (HA-CXCR1-ER) primers encoding the Cterminal 14 amino acid segment of the α 2c -adrenoceptor were annealed to HA-CXCR1. Sense:5'AATTCAAGCATATCCTCTTTC GAAGGAGGAGAAGGGGCTTCAGGCA ATGAT 3', Antisense:5'CTAGATGATTGCCTGAAGCCC CTTCTCCTCCTTCGAAAGAGGA TATGCTTG 3'. An EcoRI site present in the sense primer and the XbaI site present in the anti-sense primer are underlined and the fragment digested and ligated downstream of the HA-CXCR1 fragment in frame in pcDNA3.
Carboxyl-terminally tagged constructs
In each case the primers were designed to amplify the CXCR1 receptor and remove the stop codon; CXCR1-GFP 
CXCR2
Human CXCR2 was used as a PCR template for all CXCR2 constructs. These were generated in a similar fashion to the CXCR1 constructs. For the N-terminally modified forms of the receptor, primers encoded the appropropriate epitope tag sequence and introduced a stop codon after the last amino acid of the receptor sequence.
FLAG-CXCR2
Sense:5'AAAAGAATTCGCCACCATGG ACTACAAGGACGACGATGATAA GGAAGATTTTAACATGGAG 3', Anti-sense: 5'AAAAGAATTCGAGAGTGGAAGTGT GCCC 3'. EcoRI sites present in both sense and antisense primers are underlined and the amplified fragment digested and ligated into pcDNA3. c-myc-CXCR2 Sense:5'AAAAGAATTCGCCACCATGG AACAAAAACTTATTTCTGAAGAAGA TCTGGAAGATTTTAACATGGAG 3' Antisense:5'AAAAGAATTCGAGAGTGGAA GTGTGCCC 3'. EcoRI sites are underlined and the amplified fragment digested and ligated into pcDNA3.
VSVG-CXCR2
Sense:5'AAAAGGTACCGCCACCATGT ACACCGACATCGAAATGAACCGC CTTGGTAAG -3', Anti-sense: 5'AAAAGAATTCGAGAGTGGAAGTGT GCCC3'. The KpnI and EcoRI sites present in the sense and anti-sense primers respectively are underlined and the amplified fragment digested and ligated into pcDNA3.
For the C-terminally modified forms of the receptor, primers were designed to amplify the sequence and remove the stop codon. 
CXCR2-GFP

Cell membrane preparation
Pellets of cells were resuspended in 10mM Tris, 0.1mM EDTA, pH 7.4 (TE buffer) and the cells homogenized using 40 strokes of a glass on Teflon homogenizer. Samples were centrifuged at 1000 x g for 10 min at 4 o C to remove unbroken cells and nuclei. The supernatant fraction was removed and passed through a 25 gauge needle 10 times before being transferred to ultra-centrifuge tubes and subjected to centrifugation at 50000 x g for 30 min. The supernatant was discarded and the pellet resuspended in TE buffer. Protein concentration was assessed, membranes diluted to 1mg/ml and stored at -80 o C until required.
Radioligand binding
Reaction mixtures were established in a volume of 100µl containing 5µg of membrane protein, 100pM [ 125 I]IL8, and a range of concentrations of nonradiolabelled IL8. Samples were incubated for 90 min at room temperature prior to filtration through Whatman GF/C filters. Data was analysed using Graphpad Prism, and IC 50 values determined via non-linear regression using one site competition analysis. The equilibrium dissociation constant for the binding of IL8 was calculated using the Cheng-Prusoff equation (31) .
Co-immunoprecipitation studies
Cells were harvested 24 h following transfection and resuspended in RIPA buffer (50 mM HEPES, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 10 mM NaF, 5 mM EDTA, 0.1 mM NaPO 4 , 5% ethylene glycol). The cell pellet was disrupted as above and placed on a rotating wheel for 1 h at 4°C. Samples were then centrifuged for 10 min at 14000 x g at 4°C and the supernatant transferred to a fresh tube containing 200µl of 1X RIPA and 50µl of Protein G beads (Sigma) to pre-clear the samples. Following incubation on a rotating wheel for 1 h at 4°C the samples were recentrifuged at 14000 x g at 4°C for 1 min and protein concentration of the supernatant determined. Samples containing equal protein amounts were incubated overnight with 40µl Protein G beads, 5µg M2 anti-FLAG antibody (Sigma) at 4°C on a rotating wheel and fractions reserved to monitor protein expression in the cell lysates. Samples were centrifuged at 14000 x g for 1 min at 4°C and the Protein G beads washed with 3 times with RIPA buffer. Following addition of Laemmli buffer and heating to 85°C for 4 min, both immunoprecipitated samples and cell lysate controls were revolved by SDS-PAGE using pre-cast 4-12% acrylamide Novex Bis-tris gels (Invitrogen BV). Proteins were transferred onto nitrocellulose. These membranes were incubated in 5% (w/v) low fat milk, 0.1% Tween 20/PBS (v/v) solution at room temperature on a rotating shaker for 2 h and then with primary antibody overnight in 5% (w/v) low fat milk, 0.1% Tween 20/PBS (v/v) solution at 4°C. The membrane was washed 3 x in 0.1% Tween 20/PBS before addition of secondary antibody. Following further washes the membrane was subsequently developed using ECL solution (Pierce).
Confocal laser scanning microscopy
Cells were imaged using a laser scanning confocal microscope (Zeiss LSM 5 Pascal) equipped with a 63x oil-immersion Plan Fluor Apochromat objective lens with a numerical aperture of 1.4. A pinhole of 20 and an electronic zoom of 1 or 2.5 was used (Carl Zeiss Inc., Thornwood, NY). The excitation laser line for GFP and YFP was the 488nm argon laser with detection via a 505-530 band pass filter. Alexa 594 label was detected using a 543nm helium/neon laser and detected via a 560 long-pass filter. The images were manipulated using MetaMorph imaging software (version 6.1.3; Universal Imaging Corporation, Downing, PA). In some experiments, fixed cells were used. Cells grown on coverslips were transiently transfected and washed 3 times with icecold PBS. Cells were fixed for 10 min at room temperature using 4% paraformaldehyde in PBS/5% sucrose. The cells were washed a further 3 times in icecold PBS prior to being fixed onto microscope slides with 40% glycerol in PBS.
Fluorescent microscopy and FRET imaging in living cells
HEK293T cells were grown on poly-Dlysine treated coverslips and transiently transfected with appropriate CFP/YFP fusion proteins. Coverslips were placed into a microscope chamber containing physiological saline solution (130nM NaCl, 5mM KCl, 1mM CaCl 2 , 1mM MgCl 2 , 20mM HEPES, 10mM D-glucose pH 7.4). Cells were visualized using a Nikon Eclipse TE2000-E fluorescence inverted microscope and images obtained individually for eYFP, CFP and FRET filter channels using an Optoscan monochromator (Cairn Research, Faversham, Kent, UK) and a dichroic mirror 86002v2bs (Chroma Inc., Rockingham, VT). The filter sets used were; YFP (excitation -500/5nm; emission -535/30nm), CFP (excitation 430/12nm; emission -470/30nm) and FRET (excitation -430/12nm; emission -535/30nm). The illumination time was 250ms and binning modes 2x2.
MetaMorph imaging software was used to quantify the FRET images using the sensitized FRET method. Corrected FRET was calculated using a pixel-by-pixel methodology using the equation 3+ and anti-FLAG allophycocyanin (APC) antibodies were diluted in 50% newborn calf serum: 50% PBS to final concentrations of 5nM and 15nM respectively. Samples were mixed and incubated on a rotating wheel at room temperature for 2 h. Samples were covered in aluminium foil to minimise exposure of the fluorophores to light. Samples were centrifuged at 1000 x g for 1 minute and the antibody mix removed from the cell pellet. The pellet was then washed 2 X in ice-cold PBS and resuspended in 250µl of PBS. To investigate agonist effect on energy transfer, 90µl of cells were transferred to a fresh tube and incubated with the chosen concentration of agonist at 37ºC. To measure the energy transfer, 40µl of each sample was dispensed in triplicate into a black 384-well plate. Blank wells containing PBS were also included. Tr-FRET was determined using a Victor 2 plate reader (Packard Bioscience). Excitation was at 340nm and emission filters generated data representing donor (615nm) and acceptor (665nm) fluorescence. Normalized FRET was calculated using the equation; Normalized FRET = ((A 665 -BLK)/D 615 )-C Where A 665 is the fluorescent emission from the acceptor, D 615 is the fluorescent emission from the donor and BLK represents the background reading at 665nm from wells containing PBS. C represents the cross-talk between the donor and acceptor windows for the samples incubated with only anti-c-myc Eu 3+ and is equal to A 665 -BLK/D 615 .
BRET 2
Single Point BRET 2 Cells were washed twice in PBS supplemented with 1g/l glucose and resuspended in a final volume of 1ml. 160µl of cells were dispensed into a whitewalled 96 well plate (Optiplate, PerkinElmer) and either 20 µl of agonist or PBS/glucose added. If agonist was tested then the plate was incubated for 30 min at 37 o C. DeepBlueC (PerkinElmer) substrate was diluted 1:20 in PBS/glucose and the mix kept protected from light until required. 20µl of substrate was added to each well resulting in a final concentration of 10µM and BRET 2 measured using a Mithras LB940 (Berthold Technology, Bad Wildbad, Germany). Readings were taken using 410nm (band pass 80nm) corresponding to light emission resulting from Renilla luciferase catalysing the substrate to coelenteramide. Transferred energy emitted by GFP 2 was detected using a 515nm (band pass 30nm) filter and a ratiometric reading obtained corresponding to the ratio of light intensity (515nm) to light intensity (410nm). Saturation BRET 2 In saturation BRET 2 experiments cells were transfected with a constant amount of the energy donor (Renilla luciferase) construct and a varying amount of energy acceptor (GFP 2 ) construct. Cells were harvested, membranes prepared and diluted to 0.5mg/ml. BRET 2 was assessed as above for intact cells. Luminescence and fluorescence measurements were also obtained. 50µl of cell membranes were dispensed into white-walled 96-well plates (PerkinElmer) for luminescence measurements and black-walled 386-plates (Costar, Cambridge, MA) for fluorescence measurement. For luminescence measurement h-coelenterazine (5µM) was added and the plate incubated at room temperature for 30 min prior to measurement at 410nm using a Mithras LB 940. GFP 2 fluorescence was assessed using Victor 2 1420 Multilabel counter (PerkinElmer). BRET 2 readings were corrected for energy transfer resulting from bleedthrough of signal the Renilla luciferase construct expressed alone but detected in the GFP 2 channel. Fluorescence readings were corrected for endogenous fluorescence of HEK293T cell membranes alone. Graphpad Prism 4 was used to analyse data using a one site binding hyperbola equation yielding BRET MAX and BRET 50 values.
Immunostaining protocol
Cells were grown onto coverslips and transiently transfected. 24 h later medium was removed and the cells incubated with 20mM HEPES/DMEM containing the appropriate dilution of primary antibody for 40 min at 37 o C in 5% CO 2 . IL8 (50nM) was added and the coverslip incubated for 30 min. Following 3 washes with PBS cells were fixed by incubating with 4% paraformaldehyde in PBS/5% sucrose for 10 min at room temperature. Following 3 further washes cells were permeabilized with 0.15% Triton-X-100/3% nonfat milk/PBS for 10 min. The coverslips were incubated with a secondary antibody (5mg/ml) conjugated to an Alexa 594 fluorophore. Following incubation for 1 h cells were washed twice in 0.15% Triton-X-100/3% nonfat milk/PBS and three times in PBS. Coverslips were then mounted onto microscope slides with 40% glycerol in PBS.
Endoplasmic reticulum trapping and quantitation studies HEK293T cells were transfected to express either HA-CXCR1 or an ER-retained version of this construct that has the Cterminal 14 amino acids of the α 2c -adrenoceptor attached to the C-terminal tail (HA-CXCR1-ER). Such cells were cotransfected with N-terminally FLAG-tagged forms of various receptors. 48h following transfection cells were harvested and counted using a haemocytometer. 5 x 10 5 cells were dispensed into individual eppendorf tubes and the cells incubated with 15nM APC labelled anti-FLAG antibody and 1µM Hoescht nuclear stain on a rotating wheel for 1h. The cells were centrifuged at 1000 x g for 1 min and the cell pellet washed three times with PBS. The cells were re-suspended in 200µl PBS and 40µl replicates dispensed into a black 384-well plates. Fluorescence corresponding to APC was quantified using a Victor 2 1420 Multilabel counter (PerkinElmer). Controls measured fluorescence in similarly treated but nontransfected HEK293T cells and this value subtracted from the other readings. To ensure equal cell number between wells, fluorescence representing Hoechst staining was measured in parallel. Such data ensured well to well cell number variation was less than 20%.
cAMP measurements
The inhibition of forskolin-stimulated cAMP generation was determined using the HitHunter cAMP XS assay kit (32) (DiscoverX, Birmingham, U.K). Transfected cells were harvested and resuspended in 1X PBS containing 0.5mM isobutylmethylxanthine. Cells were dispensed into white-walled 96 well plates (Optiplate, PerkinElmer) at approximately 30,000 cells/well and incubated with 10µM forskolin and varying concentrations of GRO-α for 30 minutes at 37°C. The assay kit was then used in accordance with the manufacturers' instructions and luminescence detected using a Mithras LB940 (Berthold Technology, Bad Wildbad, Germany).
Results
The CXCR1 and CXCR2 receptors share interleukin 8 (IL8) as a high affinity agonist ligand. Because a significant number of both N-and C-terminally modified variants of the human forms of these two receptors were to be utilized in these studies we initially demonstrated that such modifications did not prevent IL8-mediated binding and internalization of the receptors.
Following introduction of the c-myc epitope tag sequence into the extreme Nterminus of both the CXCR1 and CXCR2 receptors these constructs were expressed transiently in HEK293T cells. Both constructs were shown to be located predominantly at the cell surface ( Figures  1a, b) . Following treatment of these cells with 50nM IL8 for 30 min a substantial fraction of both modified receptor constructs were re-located into punctate intracellular vesicles (Figures 1a, b) . Equivalent experiments using N-terminally FLAG-tagged forms of the receptors produced similar results (data not shown). Both the CXCR1 and CXCR2 receptors were also modified by the addition of a variety of forms of the Aequoria victoria green fluorescent protein (GFP) to the Cterminal tail. As with the N-terminally modified variants, transient expression in HEK293T cells of the CXCR1 and CXCR2 receptors tagged with, for example, the bioluminescence resonance energy transfer (BRET) acceptor competent fluorescent protein GFP 2 resulted in a predominantly plasma membrane localization (Figures 1c,  d ) and treatment with 50nM IL8 for 30 min also caused marked internalization into punctate vesicles (Figures 1c, d) . Forms of the CXCR1 and CXCR2 receptors with the BRET energy donor Renilla luciferase linked in-frame to the C-terminus were also effectively delivered to the cell surface following transient expression in HEK293T cells (Figure 1e and data not shown). Modification of the receptors did not alter the binding affinity for IL8. Direct comparisons of the specific binding of [ 125 I]IL8 to the unmodified CXCR1 receptor and its self-competition by nonradiolabelled IL8, with forms of this receptor N-terminally modified to include the c-myc, FLAG or HA epitope tags or with forms of the receptor C-terminally labelled with GFP 2 , cyan fluorescent protein (CFP), yellow fluorescent protein (YFP) or Renilla luciferase indicated each to bind the ligand with pK i close to -9.5 M (Table 1) . Similarly, N-terminal modification of the CXCR2 receptor with each of the FLAG, c-myc or VSV epitope tags, or addition of CFP, YFP, GFP 2 or Renilla luciferase to the C-terminal tail did not alter the affinity of this receptor to bind IL8 (Table 1) . Based on the specific binding of 100pM [
125 I]IL8 and the calculated K i values for IL8, expression levels of the various forms of CXCR1 and CXCR2 were estimated. These ranged from 50-500 fmol/mg membrane protein and as previously noted by (33) , for equal amounts of transfected cDNAs, levels of the CXCR1 constructs were higher than for the equivalent CXCR2 variant. Protein-protein interactions indicative of quaternary structure of GPCRs have been monitored in a range of ways. The most widely used has been the coimmunoprecipitation of differentially tagged but co-expressed polypeptides. Coexpression of both N-terminally c-myc and FLAG-tagged forms of the CXCR1 receptor allowed their coimmunoprecipitation ( Figure 2a ). Following immunoprecipitation with anti-FLAG antibody, samples were resolved by SDS-PAGE and immunoblotted with antic-myc antibody. This resulted in detection of principally a 38kDa polypeptide with small amounts of a band of some 80kDa that suggests a fraction of the immunoprecipitated dimer/oligomer was not effectively separated by the SDS-PAGE conditions employed (Figure 2a) . No antic-myc reactive bands were present in the immunoprecipitates when either the FLAG or c-myc-tagged forms of CXCR1 were expressed individually, although direct immunoblots of lysates produced from such cells confirmed the expression of the individual forms of the CXCR1 receptor in each the samples anticipated (Figure 2a) . Equally, mixing of cell lysates expressing either FLAG-CXCR1 or c-myc-CXCR1 prior to immunoprecipitation with the anti-FLAG antibody did not result in coimmunoprecipitation, indicating that coexpression was required to allow interaction. Equivalent experiments using FLAG and c-myc-tagged forms of CXCR2 produced equivalent data (Figure 2b) , with the monomer migrating as a polypeptide of some 35 kDa. Again, a small fraction of the co-immunoprecipitated anti-c-myc immunoreactivity remained as a dimer following migration through SDS-PAGE. Co-expression of FLAG-CXCR1 with cmyc-CXCR2 also allowed their coimmunoprecipitation (Figure 2c) , consistent with the capacity of these two closely related GPCRs to form a heterodimer/oligomer complex in cells in which they are co-expressed. (Figure 3 ). Equivalent studies with CFP and YFP-tagged forms of the CXCR2 receptor also resulted in positive FRET signals when the two forms of this receptor were co-expressed ( Figure 4) . As with the CXCR1 receptor, these effects were selective as only weak interactions could be recorded between the CXCR2 receptor and the α 1A -adrenoceptor-YFP (Figure 4) . Finally, co-expression of CXCR1-CFP and CXCR2-YFP, or coexpression of the alternate CXCR2-CFP and CXCR1-YFP pairing, also generated strong positive FRET signals indicative of the capacity of these two related receptors to form a hetero-dimer/oligomer complex ( Figure 5 ). As all of these experiments were conducted in the absence of IL8, these studies are also consistent with both homoand hetero-dimer/oligomers of these receptors forming constitutively without need for agonist. Both the co-immunoprecipitation and FRET imaging studies offer initial insights into the capability of the CXCR1 and CXCR2 to form homo-dimeric/oligomeric and, when co-expressed, heterodimeric/oligomeric complexes. However, such studies can offer little insight into the relative propensity of pairs of GPCRs to interact. To assess this we employed saturation bioluminescence resonance energy transfer 2 (saturation BRET 2 ) experiments. Proteins tagged with Renilla luciferase and with GFP 2 can allow BRET upon addition of an appropriate substrate for the luciferase if interactions between the partner proteins bring the luciferase and the GFP 2 into proximity (35) . By varying the ratio of energy acceptor (the GFP 2 -tagged protein) and energy donor (the luciferasetagged protein) BRET 2 saturation curves can be generated in which half-maximal signal provides a measure of the relative affinity of protein-protein interactions (12, 36 Figure 6A ). By contrast, when CXCR1-Renilla luciferase was co-expressed with the isolated GFP 2 in varying ratios no measurable BRET 2 signal was obtained ( Figure 6A) experiments in which CXCR2-Renilla luciferase and CXCR2-GFP 2 were coexpressed also confirmed the capacity of this receptor to form homo-dimer/oligomers and the measured BRET 2 50% of 2.2 +/-0.1 ( Figure 6A ) indicated that the affinity of interactions between these forms of the CXCR2 receptor is at least as high as for the CXCR1 receptor. Co-expression of various ratios of CXCR1-Renilla luciferase and CXCR2-GFP 2 confirmed the capacity of these two receptors to heterodimerize/oligomerize and, because the BRET 2 50% ratio in these experiments, 3.6 +/-0.1 was highly similar to those obtained for the homo-dimer pairings, suggests the propensity of CXCR1 and CXCR2 to hetero-dimerize is similar to that of the individual receptors to form homo-dimers. Again, it was important to obtain clear negative controls. To do so we coexpressed CXCR2-Renilla luciferase along with a GFP 2 -tagged form of the α 1A -adrenoceptor that we have used in previous studies (12) . BRET 2 signals produced from this pairing were low and, importantly, were fit adequately by a straight line in which signal increase was a direct reflection of the energy acceptor to energy donor ratios ( Figure 6A ) suggesting that this pair of GPCRs has no substantial mutual affinity. As a ratiometric measure, BRET 2 signals that reflect specific proteinprotein interactions should be independent of absolute expression levels. Increasing signals with receptor expression levels may reflect physical crowding that is not related to true interactions. Such effects have been termed bystander effects (36) . Although the expression levels measured by the specific binding of [ 125 I]IL8 (see earlier) were far lower than those previously reported to be required to observe bystander effects (36) we tested this directly. HEK293 cells were transfected with different amounts of CXCR1-Renilla luciferase (energy donor) and CXCR1-GFP 2 (energy acceptor) cDNAs but in each case in a 1:1 ratio. Differing expression levels of CXCR1-Renilla luciferase were monitored by direct measurement of luciferase activity using h-coelenterazine as substrate to generate the luminescent signal because the emission spectrum from oxidation of this substrate is not suited for energy transfer to GFP 2 (12) . Luminescence increased across the full range of cDNA amounts employed ( Figure  6B ). Similarly, relative levels of CXCR1-GFP 2 were monitored by direct fluorescence and increased linearly with cDNA amount transfected ( Figure 6B ). Despite this, the BRET 2 ratios recorded in such cells upon addition of DeepBlueC as luciferase substrate were not different for the varying levels of the constructs expressed ( Figure 6B ). As monitored using BRET 2 neither homodimeric CXCR1 and CXCR2 nor heterodimeric CXCR1-CXCR2 interactions were modified by the addition of IL8 (Figure 7) , indicating, as in the FRET imaging experiments, that each of these interactions is generated constitutively and not in response to agonist binding. Because the Renilla luciferase and GFP 2 tags that act as BRET 2 partners are both inside intact cells it is impossible to determine the cellular location of the dimeric/oligomeric GPCRs from such studies. Although the distribution of GFP 2 - tagged forms of both CXCR1 and CXCR2 monitored by confocal microscopy indicated significant plasma membrane delivery ( Figure 1 ) this can only be fully established by 3D-cellular reconstruction from z-plane confocal slices through a single cell. We therefore wished to confirm quaternary structure of CXCR1 and CXCR2 homo-and hetero-dimers at the surface of transfected cells and to assess whether interactions between at least this population of these receptors might be modulated by IL8. To do so we employed time-resolved fluorescence resonance energy transfer (Tr-FRET) following expression of N-terminally FLAG and cmyc epitope-tagged forms of the CXCR1 and CXCR2 receptors. Addition of a combination of Eu 3+ -labelled anti-c-myc antibody, as long-lived energy donor, and allophycocyanin (APC)-labelled anti-FLAG antibody as energy acceptor to intact HEK293 cells co-expressing N-terminally c-myc-and FLAG-tagged forms of the CXCR1 receptor resulted in a substantial signal corresponding to Tr-FRET ( Figure  8 ). This was not observed with addition of only the Eu 3+ -labelled anti-c-myc antibody or the APC-labelled anti-FLAG antibody (data not shown). Signals were also negligible when both labelled antibodies were added to mixed cell populations each expressing either c-myc-CXCR1 or FLAG-CXCR1 alone ( Figure 9 ). Equivalent results were obtained with expression of cmyc and FLAG-tagged forms of CXCR2 ( Figure 9 ). Equally strong Tr-FRET signals were also obtained from cells co-expressing pairs of N-terminally tagged CXCR1 and CXCR2 receptors (Figure 9) , with results being equivalent whether CXCR1 or CXCR2 acted to bind the energy donating Eu 3+ -labelled anti-c-myc antibody ( Figure  8 ). As in the BRET 2 experiments addition of IL8 (100nM, 15 min) did not modify the Tr-FRET signal (Figure 8 ).
Co-immunoprecipitation experiments
Recent studies have provided evidence that protein-protein interactions involving GPCRs can occur at an early stage in biogenesis and in advance of delivery to the cell surface (16) (17) . To examine this for CXCR1/CXCR2 receptors we employed an endoplasmic reticulum trapping strategy. As shown earlier (Figure 1) , following transient expression in HEK293 cells a substantial fraction of both N and Cterminally modified forms of the CXCR1 receptor is delivered to the cell surface. Following transient expression of Nterminally HA-tagged CXCR1 in HEK293 cells, antibody staining in nonpermeabilized and permeabilized cells confirmed substantial membrane delivery of this construct (Figure 9a ). By contrast, although a fraction of a N-terminally HAtagged form of α 2C -adrenoceptor was able to reach the cell surface and hence be detected without cellular permeabilization ( Figure 9a ) the vast majority of this construct was retained intracellularly, with a distribution pattern consistent with labelling of the endoplasmic reticulum (Figure 10a) . Indeed, previous work has shown this to reflect the presence of an endoplasmic reticulum retention motif within the C-terminal 14 amino acids of α 2C -adrenoceptor (37) (38) . We generated a form of the CXCR1 receptor with these 14 amino acids from the α 2C -adrenoceptor added to the C-terminal tail. In contrast to the wild type CXCR1 receptor, little of the modified CXCR1 receptor was trafficked to the cell surface (Figure 9a ). This was not a reflection of poor expression of this construct. Following permeabilization of the cells, the modified CXCR1 receptor (HA-CXCR1-ER) was shown to be largely intracellular (Figure 9a) . The cell surface expression of FLAG-CXCR1 was monitored when this construct was coexpressed with either HA-tagged wild type CXCR1 or HA-CXCR1-ER. Only some 50% as much of the FLAG-tagged wild type CXCR1 reached the cell surface when its expression partner was HA-CXCR1-ER (Figure 9b ). The same was true when the ability of FLAG-CXCR2 to reach the cell surface was monitored. Co-expression with HA-CXCR1-ER resulted in a substantial reduction of cell surface FLAG-CXCR2 compared to when this receptor was coexpressed with HA-CXCR1 ( Figure 9b ). As in the BRET 2 experiments we wished to establish the selectivity of the endoplasmic reticulum trapping strategy. When FLAG--α 1A -adrenoceptor was employed, cell surface delivery of this construct was the same whether co-expressed with HA-CXCR1 or HA-CXCR1-ER (Figure 9b) , confirming a lack of significant interactions between the CXCR1 receptor and the α 1A -adrenoceptor.
To assess if interactions between the CXCR1 and CXCR2 receptors altered potency or functionality of ligands we examined the ability of the CXCR2 selective agonist GRO-α to inhibit cAMP generation stimulated by forskolin (10µM) in cells individually expressing CXCR1 or CXCR2, cells individually expressing the two receptors but mixed prior to the assay or cells co-expressing CXCR1 and CXCR2. As anticipated, GRO-α -mediated inhibition of cAMP production was 30 fold more potent in cells expressing CXCR2 than CXCR1 (Figure 10 ). In cells co-expressing CXCR1 and CXCR2 the potency of GRO-α was intermediate between the values for the individually expressed receptors and was not different from that noted for cells individually expressing CXCR1 or CXCR2 that were mixed prior to assay (Figure 10 ).
Discussion
It has become widely accepted that many members of the rhodopsin-like, family A class of GPCRs have the capacity to homodimerize and as both direct experimental data (39) and models based on the dimensions of GPCRs and G proteins (14) are consistent with a GPCR dimer binding a single G protein hetero-trimer, dimerization may be integral to GPCR function (6) . There is increasing evidence that dimers of many GPCRs form during synthesis and maturation and that this can be important for cell surface delivery (16) (17) . Equally, there are many examples in which the extent of GPCR dimerization is unaffected by the binding of agonist ligands and indeed, where the GPCR is internalized into the cell as a dimer/oligomer in response to agonist challenge (40) (41) . The chemokine receptors are members of the class of family A GPCRs (25) . However, although the literature is complex (see (5) for review), a number of reports on specific chemokine receptors are inconsistent with the simple pattern outlined above. For example, early studies indicated the chemokine SDF-1α to produce dimerization of the CXCR4 receptor that was almost undetectable in the absence of the ligand (19) . In complete contrast, combinations of BRET and sedimentation studies indicated the CXCR4 receptor to be a constitutive dimer that was unaffected by the presence of SDF-1α (22) . Ligand-induced dimerization has also been reported for the CCR2 receptor on addition of monocyte chemoattractant protein-1 (18) and the capacity of HIV-1 to utilize the CCR5 receptor as a 'co-receptor' for cell entry is blocked by dimerization of the receptor produced by chemokine agonists (42) . However, the CCR5 receptor has also been reported to be both a ligand independent, constitutive dimer/oligomer (21) and a monomer (22) . At this time a clear pattern is therefore difficult to discern. In many other aspects of structure, function and regulation family A GPCRs show considerable parsimony, as might be expected for a family of homologous proteins (43) and thus we wished to use as wide a range of approaches as possible to re-examine aspects of the interactions between CXCR1 and CXCR2 receptors. In contrast to previously published work (23), herein we demonstrate the ability of the CXCR1 receptor, as well as the CXCR2 receptor, to form a homo-dimer/oligomer and that when co-expressed the CXCR1 and CXCR2 receptors are able to heterodimerize/oligomerize. Such conclusions are based on data from five distinct techniques, including, coimmunoprecipitation, resonance energy transfer approaches and intracellular trapping by an ER-retained version of theCXCR1 receptor. Three of these approaches were particularly enlightening. Firstly, the ER-trapping strategy showed that an ER-retained form of the CXCR1 receptor limited cell surface delivery of Nterminally FLAG-tagged forms of both CXCR1 and CXCR2. Specificity of this assay was established by unaltered cell surface delivery of a N-terminally FLAGtagged form of the α 1A -adrenoceptor, a receptor shown by other means to interact with the CXCR1 and CXCR2 receptors with minimal affinity. This assay established that CXCR1 homo-dimerization and CXCR1-CXCR2 hetero-dimerization occurs, as previously established for the β 2 -adrenoceptor (17), during receptor synthesis and maturation. Secondly, the application of cell surface Tr-FRET showed that constitutively established forms of each of CXCR1 and CXCR2 homodimers/oligomers and CXCR1-CXCR2 hetero-dimers were present at the surface of cells in the absence of IL8 and that such interactions were not modified substantially by the presence of the agonist. Thirdly, use of saturation BRET 2 techniques (36) showed that the propensity of CXCR1 and CXCR2 to generate hetero-interactions was not different from their ability to homodimerize. Thus, unless specific cellular mechanisms exist in particular cell types to ensure that mRNAs encoding these GPCRs are trafficking to different sections of the ER machinery then it must be expected that CXCR1-CXCR2 hetero-dimers as well as the corresponding homo-dimers will exist and in ratios determined by expression levels of the individual receptors. Although experimental evidence indicates the hypothesis that the propensity of pairs of distinct GPCRs to form hetero-dimers will simply reflect the sequence homology between individual GPCRs (44) is too simplistic (see 5 for review) the high similarity between the CXCR1 and CXCR2 would certainly be consistent with the equivalent apparent interaction affinities for homo-and hetero-dimerization that we observed in the BRET saturation studies. Similarly, for the three opioid receptor subtypes, very recent BRET saturation studies have indicated similar interaction affinities between all possible heterodimeric pairs (45) although earlier, technically more limited studies, had indicated that certain pairs were unable to hetero-dimerize (46) . In each of these regards then the CXCR1 and CXCR2 receptors behave as 'typical' family A GPCRs. As noted above, the issue of ligand dependence of GPCR dimerization has been particularly contentious for the chemokine receptors. A substantial number of RET-based experiments have shown small effects of agonist ligands above substantial signals corresponding to constitutive dimers/oligomers (see (5) for review). Despite this, an emerging consensus favours family A GPCRs with small endogenous ligands that bind within the seven transmembrane domains predominantly as constitutive dimers. Observed effects of ligands are then most likely due to conformational alterations within the complex resulting in small changes in the orientation or distance between the RET reporters (47). However, for family A GPCRs with larger peptide and small protein ligands that have contact points for binding outwith the topology of the seven transmembrane helix bundle the situation is more complex. Each of neuropeptide Y Y4 receptor (48) , TSH receptor (49) and type A cholecystokinin receptor (50) dimers have been reported to be constitutively formed but dissociated by agonists whereas, by contrast, the GnRH (51), lutropin (52) and a number of other receptors, have been reported to increase in aggregation state in response to agonists. As such, hetero-dimerization between GPCR pairs might alter ligand pharmacology and function, particularly for receptors such as the chemokine receptors where ligand binding is defined at least in part by elements in the extracellular Nterminal region of the receptor. Indeed, recent studies (53) have provided evidence for negative binding co-operativity within CCR5-CCR2b hetero-dimers. As such, in the current studies, we examined if the effectiveness or potency of the CXCR2 selective agonist ligand GRO-α to inhibit cAMP production was affected by coexpression of CXCR1 and CXCR2. It was not, thus at least for this ligand, which has relatively modest selectivity between the two GPCRs there was no indication of the hetero-dimer displaying a distinct pharmacology or function. Further work, perhaps with less closely related GPCRs, will be required to explore such possibilities more effectively. For example, the ability of the CCR5 chemokine receptors to hetero-dimerize with other coexpressed GPCRs, including opioid receptors has recently been reported (54) . At the moment there is no information on the relative affinity of such interactions and therefore their likely importance for physiology and function. However, as other examples of GPCR heterodimerization, including those involving interactions between the angiotensin AT1 receptor and each of the AT2 receptor (55), the bradykinin B2 receptor (56) and the mas proto-oncogene (57) have been reported to have physiological and patho-physiological consequences, application of the type of techniques used in these studies would provide a useful starting point to understand the importance of interactions between chemokine receptors with other members of the GPCR family. Tables  Table 1 N- The affinity of IL8 to bind to wild type and each of the modified forms of the CXCR1 and CXCR2 receptors was assessed from analysis of the capacity of IL8 to compete with a single concentration (100pM) of [ 125 I]IL8 for binding. All experiments were performed on a minimum of 3 occasions using separate membrane preparations. No significant differences were noted for each of the modified constructs compared to the wild type (1-way ANOVA with Dunnetts' post test). 
